The Regeneron Pharmaceuticals story

What drives the business

• Regeneron's business combines its EYLEA eye medicines with collaboration agreements involving Sanofi and Bayer, making partner economics important alongside product demand.
• Dupixent growth lifted Regeneron's share of profits from commercializing antibodies under the Sanofi collaboration to $2.033 billion in the quarter to June 2026, compared with $1.282 billion in the quarter to June 2025.
• The transition to higher-dose EYLEA HD is reshaping the eye business, while older EYLEA U.S. sales fell 45% in the quarter to June 2026 amid competition, patient migration and lower net prices.
• Libtayo global net sales increased 30% to $489 million in the quarter to June 2026, adding another source of growth alongside Dupixent.
• Regeneron had approximately 50 product candidates in clinical development at the July 2026 release, with its midstage and late-stage pipeline driving higher research spending.

What the price assumes

At $752.25, the reverse DCF implies free cash flow after stock pay grows 11.1% a year for ten years, using a 10.2% discount rate.

That compares with delivered annual growth of 32.9% over the last 10 years and the TenQ check's 18.5% bar, which slows that record halfway toward 4%.

The implied growth rate is below that bar, but revenue growth over the last twelve months was 9.3%, and $987 million of stock-based pay accompanied $3.8 billion of free cash flow.

Value REGN on your own assumptions

What could change the story

• EYLEA HD growth has not stopped the decline in combined U.S. eye medicine sales, and competition, including biosimilars, reimbursement decisions and pricing pressure could further change the franchise's economics.
• Growth passed 2 of 6 TenQ checks, with revenue growth of 9.3% over the last twelve months below the sector comparison of 20.4%, despite acceleration from the three-year annual pace of 5.6%.
• Pipeline spending does not guarantee new medicines, as the fianlimab combination trial announced in May 2026 failed to reach statistical significance on its primary endpoint.
• GAAP gross margin on net product sales fell to 78% from 83% in the quarter to June 2026 because of unabsorbed manufacturing costs in Limerick, although production returned to normal by period end without affecting product availability.
• The Sanofi and Bayer agreements can be terminated, while EYLEA patent litigation and pending government civil proceedings add legal uncertainty.

What to watch next

• The next releases will show how much the Sanofi Development Balance repayment lifts collaboration profits beginning in the third quarter of 2026, alongside Dupixent demand and combined EYLEA sales.
• For full year 2026, management guided to GAAP R&D expenses of $6.500 to $6.635 billion and raised GAAP gross margin guidance on net product sales to 78% to 79%, making research spending and manufacturing recovery important measures.
• Lowered capital expenditures guidance of $1.030 to $1.100 billion for full year 2026 provides a spending benchmark, while the FDA's scheduled November 2026 action date for cemdisiran is a concrete pipeline milestone.

Sources

• Regeneron Pharmaceuticals's earnings release, filed with the SEC
• Its latest 10-Q or 10-K, for the risk factors
• The REGN stock report, for every figure and check